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ABSTRACT The full primary structure of the very potent
opioid peptide dynorphin, from porcine pituitary, has been de-
termined. It is (H)Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-
Leu-Lys-Trp-Asp-Asn-Gln(OH). The synthetic peptide with this
sequence behaves identically to natural dynorphin in a number
ofways, and it has the same potency in the guiinea pig ileum myen-
teric plexus-longitudinal muscle bioassay. The potency is ac-
counted for by the first 13 residues.
Dynorphin is an extremely potent opioid peptide which con-
tains [Leu]enkephalin as its NH2-terminal sequence. Originally
isolated in small amount from a commercial porcine pituitary
preparation, its amino acid sequence could be determined with
certainty only through the 13th residue [Tyr-Gly-Gly-Phe-Leu-
Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys] (1). Antisera to synthetic
dynorphin-(1-13) were then developed for a highly specific and
sensitive radioimmunoassay, with which it has been determined
that dynorphin is a widely distributed neuropeptide (2-4) and
evidently interacts in vivo with its own unique type of opiate
receptor (5, 6). By using this radioimmunoassay as a guide to
purification, and with the aid of an immunoaffinity procedure,
we have now isolated biologically active dynorphin from porcine
pituitary in sufficient amount to establish the entire amino acid
sequence.
MATERIALS AND METHODS
In the radioimmunoassay (7), synthetic dynorphin-(1-13)
(Peninsula Laboratories, San Carlos, CA) was used as the stan-
dard for measurement of immunoreactive dynorphin (ir-dy-
norphin). Bioassay used the guinea pig myenteric
plexus-longitudinal muscle preparation as described (8, 9). Pro-
tein was determined by the Lowry procedure (10) with bovine
serum albumin as standard. Amino acid analysis at Palo Alto
used standard routines and "Hi-Phi" buffer systems with the
Dionex (Sunnyvale, CA) amino acid analyzer kit. Amino acid
analysis at Pasadena was carried out on the Durrum D-500 ana-
lyzer. Sequence determinations were carried out as described
(11).
Two sources ofdynorphin were used. The first was the same
melanotropin concentrate (MC) from which dynorphin was pre-
viously obtained (1). This powder is a dried oxycellulose adsor-
bate of an extract of whole porcine pituitaries, generously fur-
nished by J. D. Fisher (Armour, Kankakee, IL). Several 20-g
batches were processed. The second source was 2500 lyophi-
lized porcine posterior pituitaries (i.e., neurointermediate
lobes; PP), purchased from Pel-Freez. Dynorphin from both
sources was isolated in a pure state in five steps. Table 1 sum-
marizes the amounts processed, yields, and specific activities
at each step.
Step 1. Extraction. Dry PP or MC material was weighed,
pulverized, and then extracted in boiling acetic acid (0.1 M or
1.0 M, 50 ml/g) for 30 min with stirring. This solvent yields
more ir-dynorphin than the acidified methanol used previously.
After centrifugation (8000 x g, 40 min, 20C) the supernatant
solution was removed, and the pellet was resuspended in cold
acetic acid and centrifuged again. The yield from PP was the
same with either concentration of acetic acid, but 1.0 M was
required for maximal yield from MC.
Step 2a. CM-Sephadex batch procedure. This desalting step
was not required for PP extracts. Extracts and wash solutions
containing MC material were loaded onto CM-Sephadex (Phar-
macia, C-25, prewashed with 1.0 M acetic acid, 1 g per g ofMC
starting material). After washes with 1.0 M acetic acid and then
water (300 ml each), the material was eluted with MeOH/0.3
M HCl, 1:1 (vol/vol), at room temperature. The eluate was
diluted with 2 vol of 0.1 M acetic acid. Subsequent procedures
were identical for PP and MC.
Step 2b. Precipitation. The 0.1 M acetic acid solution was
adjusted to pH 8.6 with NH40H. The precipitate that was
formed represented 10-20% ofthe total ir-dynorphin for PP and
60-70% for MC. After the precipitate was dissolved in MeOH/
HC1 and reprecipitated, gel permeation analysis on Sephadex
G-50 showed that the precipitate contained a 3-kilodalton (kDal)
immunoreactive material, whereas the 1.7-kDal ir-dynorphin
remained in solution. The pH 8.6 precipitates were set aside
for future study. To the supernatant solution, now 0.1 M in am-
monium acetate at pH 8.6, was added Triton X-100 (Calbio-
chem) to 0.1%.
Step 3. Cation exchange. This step takes advantage of the
strongly basic character of 1.7-kDal dynorphin, evident from
the three arginine and two lysine residues of the dynorphin-
(1-13) sequence. The solution from step 2b was loaded onto a
preequilibrated CM-Sephadex column and eluted by a linear
gradient of ammonium carbonate (0.1-1.0 M) at pH 8.6 (Fig.
1). A prominent peak of ir-dynorphin was eluted at 0.4 M am-
monium carbonate. Results with PP and MC at this step were
virtually identical, and 100- to 400-fold purifications were
typical.
Step 4a. Immunoextraction. "Lucia" antiserum, with affinity
in the low picomolar range (7), has been used to measure ir-
dynorphin in tissues (2, 4). Two steps were used to obtain a
useful immunoaffinity resin. First, synthetic dynorphin-(1-13)
was coupled to cyanogen bromide-activated Sepharose 4B in
order to obtain affinity-purified antibodies from the antiserum
(12). These were coupled to Sepharose 4B, and this resin was
Abbreviations: ir, immunoreactive; MC, melanotropin concentrate;
PP, posterior pituitary; kDal, kilodalton; HPLC, high-performance
liquid chromatography; IC50, concentration for 50% inhibition.
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Table 1. Steps in purification of dynorphin
Recovery of
Amount of dynorphin in
dynorphin, original Protein, Purity,
Step Source nmol extract, % mg %
1. Extract PP 356 100 1,190 0.064
MC 261 100 10,800 0.0052
2a. Eluate from CM-
Sephadex batch
procedure PP* - - - -
MC 154 59 2,830 0.012
2b. Supernatant after pH
8.6 precipitation PP 319 89 1,190 0.058
MC 58 22 1,560 0.0080
3. Eluate from'cation.
exchange PP 178 50 5.29 7.4
MC 49 19 3.31 3.2
4a. Immunoextraction PP 114 32 - -
MC 29 11 -
4b. Eluate from CM-
Sephadex
adsorption PP 95 27 - -
MC 21 8.0 - -
5. Eluate from HPLC PP 29 8.0 0.062t 100
MC 10 3.8 0.021 100
The numbered steps are described under Materials and Methods. Amounts of dynorphin were deter-
mined by radioimmunoassay using synthetic dynorphin-(*1-13) as standard. Protein was determined ac-
cording to Lowry et al. (10) but was below the detection limit by this method beyond step 3. Percentage
purity is 100 times the specific activity (nmol/mg of protein) divided by thatof pure dynorphin (465 nmol/
mg). Data are for a typical work-up.
* This step was not necessary in the PP work-up.
t Calculated from the amount of pure ir-dynorphin.
used for purification of the natural peptide. In both cases, gly-
cine was used to block unreacted active groups. Antiserum from
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FIG. 1. Purification of dynorphin from PP by cation exchange. Su-
pernatant solution from step 2 (500 ml, pH 8.6) was passed through a
CM-Sephadex column (2 x 50 cm, equilibrated at 40C with 0.1 M am-
monium carbonate in 0.1% Triton X-100, 100 ml/hr, 10,ml fractions).
A, sample loading; B, 500-ml wash with same buffer; C, start of linear
gradient (800 ml) to 1.0M ammonium carbonate in 0.1% Triton X-100.
No more ir-dynorphin was eluted by washing column with water and
then 1.0 M HCl. Each fraction was assayed for protein (broken line)
and ir-dynorphin (solid line). Major peak of ir-dynorphin, which was
eluted at 0.4 M ammonium carbonate, contained 46% (16.7 nmol) of
the initial ir-dynorphin and 0.25% (1.91 mg) of the initial protein.
Overall recoveries: ir-dynorphin, 76% (29.1 nmol); protein, 94% (756
mg).
a different rabbit had properties apparently identical to those
of "Lucia," and an affinity resin prepared with it was used
sometimes.
The pooled fractions from step 3 containing ir-dynorphin
were subdivided for immunoextraction with batches of resin
(capacity, 15-30 nmol in 1-2 ml). Incubation was carried out
at 40C overnight, with shaking. Resin was then washed with 200
ml of 0.15 M sodium phosphate (pH 7.4) containing 5% Triton
X-100, then with the same volume of phosphate buffer alone,
and finally with water. After the overnight incubation, no ir-
dynorphin remained in solution; 5-10% was detectable in the
washes, mostly in the Triton X-100 wash. The peptide was
eluted with three 10-ml portions of 0.5 M acetic acid (each for
30 min, 37C). Overall recovery at step 4a was 60-65% for PP
and 55-60% for MC, but the degree of purification is unknown
because total protein in the eluate was below the limit of de-
tection by absorbance, and we were unwilling to commit any
significant fraction of the material to a destructive assay
procedure.
Step4b. Concentration by CM-Sephadex adsorption. The 0.5
M acetic acid eluate was applied to CM-Sephadex in a small
column (0.5 ml packed volume, prewashed with 50 ml each of
1.0 M HC1, 1.0 M NaOH, and MeOH/HCl). The adsorbed
peptide was eluted with 2 ml of MeOH/HCl.
Step 5. High-performance liquid chromatography (HPLC).
Portions (1 ml) of the MeOH/HCl eluate from step 4b were
injected onto a reverse-phase HPLC column. Fig. 2 shows a
typical elution diagram for PP material; an identical result was
obtained with MC material. A single symmetrical peak of ir-
dynorphin and absorbance was eluted at exactly the same po-
sition as the major peak ofir-dynorphin in a crude MeOH/HCl
extract of starting material (not shown), indicating that frag-
mentation or derivatization did not occur during purification.
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FIG. 2. Preparative reverse-phase HPLC of dynorphin from PP. A
Waters Associate system was used with a pBondapak C18 column (3.9
x 300 mm). Initial conditions: 15% acetonitrile in 5mM trifluoroacetic
acid. Simultaneous with sample injection, the linear gradient was
started, to 35% acetonitrile in 5 mM trifluoroacetic acid in 30 min at
1.5 ml/min; fraction volume, 0.6 ml. Broken line, absorbance at 254
nm; solid line, ir-dynorphin. Elution positions of markers: A, dynor-
phin-(1-13), 26.0% acetonitrile; B, HPLC-purified monoiodinated['25Ildynorphin-(1-13) internal standard, 28.4%. PP dynorphin was
eluted at 29.2% acetonitrile.
A second and steeper gradient, from 35% to 90% acetonitrile
in 10 min (not shown), yielded no more ir-dynorphin. The elu-
tion position of natural dynorphin shows that it is more hydro-
phobic than the synthetic tridecapeptide. Fractions containing
ir-dynorphin were pooled. Samples from this pool (both PP and
FIG. 3. Bioassay of dynorphin: typical record in the bioassay of
pure PP dynorphin (8, 9). Electrically stimulated twitch of guinea pig
longitudinal muscle occurs every 10 sec. (Upper) Dynorphin from step
5 (see Fig. 2),2.73 pmol as measured by radioimmunoassay, was added
at point marked by dot. Gap in record indicates complete replacement
of bath solution by fresh Ringer bicarbonate solution; note slow re-
covery of twitch amplitude. (Lower) Dot at left indicates addition of
dynorphin, as above. Second dot shows addition of naloxone hydro-
chloride to final concentration of 200 nM.
MC work-ups) were subjected to bioassay and were sent to Pas-
adena (frozen on dry ice) for sequence and composition
determinations.
Enzyme Digestion Procedures. Tryptic fragments were pro-
duced from pure dynorphin, both PP and MC. Dynorphin (5
nmol) from step 5 was treated with trypsin (Sigma, diphenyl-
carbamoyl chloride-treated, 10 Ag) in 400 A1d of0.15 M sodium
phosphate, pH 7.4/0.1% Triton X-100 at 370C for 2 hr. Dy-
norphin-(1-13) was treated identically. After acidification with
HC1, digests were injected onto an Altex LiChrosorb C18 re-
verse-phase HPLC column (5 Am, 4.6 X 250 mm) and eluted
as described in Fig. 3. Absorbance was monitored at 254 and
228 nm. As expected, a single fragment absorbing at 254 nm was
obtained from dynorphin-(1-13) (28.0% acetonitrile, A228/A2u
= 23), which was assumed to be dynorphin-(1-6). Two such
fragments were obtained from PP or MC dynorphin. One was
identical to that from dynorphin-(1-13). The second fragment
in each case was eluted earlier in the gradient (PP, at 23.6%
acetonitrile; MC, at 23.8% acetonitrile) and had a different ratio
ofabsorbances at the two wavelengths (PP, 10.6; MC, 10.4), as
expected for a tryptophan-containing peptide. These fragments
from PP and MC were collected from HPLC, frozen, and sent
to Pasadena for sequence determination.
Carboxypeptidase A (Sigma, Type I, diisopropyl fluoro-
phosphate-treated) was used to confirm the identity of the
Table 2. Amino acid sequence determinations
Cycle Amino acid
1 Tyr
Ser
2 Gly
3 Gly
4 Phe
5 Leu
6 Arg
7 Arg
8 Ile
9 Arg
10 Pro
11 Lys
12 Leu
13 Lys
14 Trp
15 Asp
16 Asn
17 Gln
18 None
19 None
PP dynorphin,
pmol
Intact peptides
865
210
440
450
716
786
460
540
500
400
123
215
330
200
104
55
38
27
COOH-Terminal tryptic fiagments
1 Leu 725
Ser 120
2 Lys 455
3 Trp 122
4 Asp 125
5 Asn 58
6 Gln 47
7 None
8 None
MC dynorphin,
pmol
965
205
308
417
765
827
275
351
550
217
135
170
505
198
145
72
66
26
590
77
360
98
84
25
22
Method of sequence determination in the spinning cup micro-se-
quenator is described elsewhere (11). Except for the serine contami-
nant at cycle 1 and the expected carryover from previous cycles (ap-
proximately 2% per cycle), each cycle produced only a single amino
acid, in the yields shown. Limit of detection was about 2-5 pmol. Rel-
atively higher yields of hydrophobic than of hydrophilic amino acids
are typical of the method.
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COOH-terminal amino acid. A suspension of 100 jug ofenzyme
(5 1d of20 mg/ml solution) was added to 200 1.l of glass-distilled
water and centrifuged (2000 x g, 10 min, 20C). The supernatant
solution was discarded, and the crystals were dissolved in 200
y1 of 2 M ammonium bicarbonate and then diluted to 1.0 ml
with water. In a typical experiment, 1 nmol ofpeptide was dis-
solved in 30 ,ud of 0.02 M sodium borate, pH 8.5/0.2 M NaCl/
0.1% Triton X-100 and incubated with 1 Iug (10 pA) of enzyme
at 37C. Samples (10A1) were withdrawn, diluted with 30 LI of
commercial sample diluent ("Na-S," Dionex), and injected di-
rectly into the Dionex amino acid analyzer. Blank incubations
with enzyme alone provided corrections for free amino acids
present at the outset and for those released by autodigestion.
Under standard conditions in this system, asparagine and glu-
tamine (which would not be present after acid hydrolysis) are
superimposed on the serine peak. By decreasing the temper-
ature to 250C, diluting the pH 3.25 buffer from 0.2 M to 0.06
M, and slowing the flow rate to 0.1 ml/min, it was possible to
obtain complete separation of these three amino acids.
RESULTS AND DISCUSSION
In Fig. 3, showing the bioassay ofpure dynorphin from step 5,
the upper record depicts the slow reversal on washout (13) that
is characteristic ofdynorphin; the lower record shows rapid and
complete antagonism by 200 nM naloxone.
Quantitative bioassay was carried out on seven such muscle
preparations, each estimate of the concentration for 50% inhi-
bition (IC50) being obtained by interpolation into the
log(dose)-response curve for synthetic dynorphin-(1-13) ob-
tained on the same preparation. The same solutions of PP dy-
norphin and dynorphin-(1-13) were diluted serially in MeOH/
HCl for parallel determinations in the radioimmunoassay, and
aliquots were also taken for amino acid analysis. In the bioassay,
IC50 of dynorphin-(1-13) standard was 270 ± 40 pM (mean +
SEM), and the solution ofPP dynorphin had activity equivalent
to 253 ± 34 pmoVml. Immunoreactivity of the PP dynorphin
solution was found to be 273 pmoVml, referred to dynorphin-
(1-13) standard. Thus, the specific biologic activity ofdynorphin
(i.e., biologic activity/immunoreactivity) was 0.93 ± 0.12, rel-
ative to dynorphin-(1-13). Biologic activity entirely comparable
to that shown in Fig. 3 was displayed also by MC dynorphin.
An aliquot of the same PP dynorphin was hydrolyzed in 6 M
HCl (sealed tube, 1200C, 24 hr) and then subjected to amino
acid analysis. The two prominent peaks of aspartic acid (two
residues, see below) and phenylalanine (one residue) yielded
estimates of 0.93 and 0.82 nmol of peptide, respectively. An
identical aliquot subjected to radioimmunoassay contained 0.87
nmol with reference to dynorphin-(1-13) standard. Thus, there
is complete equivalence ofPP dynorphin and dynorphin-(1-13)
with respect to both immunoreactivity and bioactivity, and ra-
dioimmunoassay measures the absolute amount of natural
dynorphin.
Sequence determinations gave unambiguous results (Table
2). The COOH-terminal tryptic fragment unexpectedly con-
tained leucine-12 as its NH2-terminal residue. Thus, the Lys13-
Trp'4 bond was resistant to digestion, although the identifica-
tion of residue 13 as lysine was unequivocal. Although trypsin-
resistant lysyl bonds are rare, they have been reported. Review
of all relevant sequences in ref. 14 revealed two instances in
which a Lys-Trp bond was not attacked by trypsin (15, 16) and
two other instances (17, 18) in which the expected tryptic di-
peptide Leu-Lys was not produced when the leucine residue
was in the NH2-terminal position, as it would be here if tryptic
cleavage occurred first at lysine-li. Trypsin resistance of Lys13-
Trp14 in dynorphin could reflect some peculiarity of secondary
structure.
Amino acid composition analysis (Table 3) was consistent with
the sequence determination, accounting for the 16 residues
other than tryptophan. It only remained to determine if the
COOH-terminal residue is free or amidated and, at the samie
time, to confirm that this residue is glutamine. Accordingly,
digestion with carboxypeptidase A was carried out. To detect
any amidase activity in the enzyme preparation, two synthetic
dynorphin analogues-one amidated at the terminus and the
other not-were treated under the same conditions as natural
PP dynorphin. After 22-hr incubation, data for release ofamino
acid in the Ser/Asn/Gln peak (as pmoVnmol peptide) were:
dynorphin-(1-13)-Ser-Asp-Asn-Gln(NH2), 4; dynorphin-(1-13)-
Ser-Asp-Asn-Gln(OH), 827; PP dynorphin, 1257. These data
are expressed as glutamine equivalents, and are corrected for
Table 3. Amino acid composition analysis
PP dynorphin MC dynorphin
Residues Residues
Amount, Blank, Corrected per mol Nearest Amount, Blank, Corrected per mol Nearest
Amino acid nmol nmol amount, nmol peptide integer nmol nmol amount, nmol peptide integer
Asp 1.16 0.08 1.08 2.1 2 1.41 0.23 1.18 2.0 2
Thr 0.05 0.05 0.00 0.0 0 0.07 0.09 -0.02 0.0 0
Ser 0.15 0.07 0.08 0.2 0 0.27 0.30 -0.03 0.0 0
Glu 0.71 0.11 0.60 1.2 1 1.00 0.35 0.65 1.1 1
Pro 0.51 0.00 0.51 1.0 1 0.66 0.07 0.59 1.0 1
Gly 1.24 0.14 1.10 2.2 2 1.78 0.51 1.27 2.2 2
Ala 0.16 0.06 0.10 0.2 0 0.19 0.15 0.04 0.1 0
Val 0.12 0.09 0.03 0.1 0 0.13 0.12 0.01 0.0 0
Met 0.00 0.00 0.00 0.0 0 0.00 0.00 0.00 0.0 0
Ile 0.48 0.01 0.47 0.9 1 0.57 0.07 0.50 0.8 1
Leu 0.88 0.02 0.86 1.7 2 1.20 0.14 1.06 1.8 2
Tyr 0.34 0.00 0.34 0.7 1 0.38 0.03 0.35 0.6 1
Phe 0.43 0.00 0.43 0.8 1 0.57 0.03 0.54 0.9 1
His 0.03 0.01 0.02 0.0 0 0.06 0.04 0.02 0.0 0
Lys 1.03 0.03 1.00 2.0 2 1.18 0.11 1.07 1.8 2
Arg 1.46 0.03 1.43 2.8 3 1.72 0.09 1.63 2.8 3
Total residues accounted for 16 16
Approximately 0.5 nmol of each peptide was hydrolyzed (1100C, 24 hr) in 6 M HCl with 0.5% phenol and then processed on the Durrum D-500
analyzer. "Blank" represents fractions collected from HPLC in blank run at same elution volume as for the dynorphin peak. Cysteine and tryptophan
are not determined. Residues per mol of peptide are computed relative to the single proline residue.
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amounts found in preincubation samples and for autodigestion
in the absence of substrate. In the same incubations, the fol-
lowing data were obtained for aspartic acid (residue 15): -10,
94, and 139, respectively.
Amino acid release after a 7-hr incubation was determined
by a modified procedure that yielded separate peaks for serine,
asparagine, and glutamine. The only amino acid that increased
during this incubation was glutamine, from 52 to 368 pmol/
nmol of peptide.
We conclude that natural biologically active dynorphin ter-
minates in a free carboxyl group, that the complete amino acid
sequence is (H)Tyr-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-
Leu-Lys-Trp-Asp-Asn-Gln(OH), and that dynorphin from PP
is identical to that from MC.
Synthetic dynorphin with the above sequence was obtained
from Peninsula Laboratories (>99% pure by thin-layer chro-
matography, electrophoresis, and HPLC) and compared with
natural dynorphin. In the HPLC system described earlier, the
elution position of the synthetic peptide was identical to that
shown in Fig. 2. Moreover, a mixture of synthetic and natural
dynorphins coeluted as a single symmetrical peak of immuno-
reactivity. Tryptic fragments were also eluted at identical po-
sitions in HPLC; and they had the same amino acid composi-
tions (including the anomalous leucine-12 and lysine-13),
confirming the trypsin resistance ofthe Lys'3-Trp'4 bond in this
peptide. Immunoreactivities ofsynthetic and natural dynorphin
were the same and were identical to the immunoreactivity of
dynorphin-(1-13). The ICw ofsynthetic dynorphin in the guinea
pig ileum bioassay was 330 ± 60pM (n = 11), indistinguishable
from that of PP dynorphin or dynorphin-(1-13). Naloxone K.,
which is a measure of receptor selectivity (6, 19), was 31 ± 2
nM (n = 6) for synthetic dynorphin and 30 ± 3 nM (n = 6) for
dynorphin-(1- 13).
The main improvements in the present procedure have been:
(a) avoidance of lyophilization, a step that we find entails large
losses; (b) use of detergents to minimize adsorptive losses; (c)
monitoring by radioimmunoassay instead of bioassay; and (d)
use of an immunoaffinity resin. The 17-residue length of dy-
norphin is close to that indicated by apparent Mr on Sephadex
G-25 when pituitary opioid peptides were first discovered in
this laboratory in 1975 (20). We have here confirmed that the
full biologic activity of this remarkably potent opioid peptide
is determined by its first 13 residues. The functional signifi-
cance of the remaining four residues is unknown; they might
make the peptide more stable in vivo.
That dynorphin plays an important physiologic role is indi-
cated by its potency, which is greater than that of any known
endogenous opioid peptide, and by the existence of a highly
specific dynorphin receptor in guinea pig myenteric plexus and
brain (5, 6, 19). This receptor is evidently the same as the opiate
receptor called K, with which certain benzomorphans are
known to interact preferentially.
Note Added in Proof. S. Tachibana has presented (at the International
Narcotic Research Conference, Kyoto, Japan, July 1981) a sequence for
dynorphin from porcine duodenum that is the same as that reported
here.
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